KZIA Stock Overview
Operates as an oncology-focused biotechnology company in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kazia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.49 |
| 52 Week High | US$15.80 |
| 52 Week Low | US$1.87 |
| Beta | 2.08 |
| 11 Month Change | 5.58% |
| 3 Month Change | 25.74% |
| 1 Year Change | -8.19% |
| 33 Year Change | -94.51% |
| 5 Year Change | -86.93% |
| Change since IPO | -99.66% |
Recent News & Updates
Recent updates
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy
Jul 06Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial
Jun 15Enrollment gets underway in Kazia's mid-stage lymphoma study
Jun 07Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer
Dec 10Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study
Dec 09Kazia stock +22% on positive paxalisib data in glioblastoma
Nov 18Shareholder Returns
| KZIA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.1% | 4.0% | 2.2% |
| 1Y | -8.2% | 18.3% | 32.6% |
Return vs Industry: KZIA underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: KZIA underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| KZIA volatility | |
|---|---|
| KZIA Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KZIA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KZIA's weekly volatility has decreased from 42% to 24% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Friend | www.kaziatherapeutics.com |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors.
Kazia Therapeutics Limited Fundamentals Summary
| KZIA fundamental statistics | |
|---|---|
| Market cap | US$25.08m |
| Earnings (TTM) | -US$17.41m |
| Revenue (TTM) | US$1.61m |
14.8x
P/S Ratio-1.4x
P/E RatioIs KZIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KZIA income statement (TTM) | |
|---|---|
| Revenue | AU$2.48m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.48m |
| Other Expenses | AU$29.26m |
| Earnings | -AU$26.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.15 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,079.32% |
| Debt/Equity Ratio | -6.3% |
How did KZIA perform over the long term?
See historical performance and comparison